Genomic copy number changes are frequently found in cancers and they have been demonstrated to contribute to carcinogenesis; and it is widely accepted that tumors with microsatellite instability (MSI) are genetically stable and mostly diploid. In the present study we compared the copy number alterations and the gene-expression profiles of microsatellite stable (MSS) and MSI colorectal tumors. A total number of 31 fresh-frozen primary tumors (16 MSS and 15 MSI) were used. Twenty-eight samples (15 MSS and 13 MSI) were analyzed with metaphase comparative genomic hybridization (CGH), nine of which plus one additional sample (4 MSS and 6 MSI) were further analyzed by cDNA-based array-CGH. Gene expression analysis was performed with six samples [3 MSS and 3 MSI, four of these used in metaphase CGH (mCGH) analysis] to identify differentially expressed genes possibly located in the lost or amplified regions found by CGH, stressing the biological significance of copy number changes. Metaphase and array-CGH analysis of two colon cancer cell lines (HTC116 and SW480, reported as MSI and MSS archetypes) gave comparable results. Alterations found by mCGH in MSS tumors were þ20, þ8q, À8p and À18q. Interestingly, 1p22, 4q26 and 15q21 were found deleted preferentially in MSS tumors, while 22q13 was found gained in MSI tumors. The regions of alterations identified by array-CGH were gains at 8q24, 16q24.3 and 20q13, and the loss of 5q21, appearing in the both types of tumors. Gene expression analysis revealed genes with specific associations with the copy number changes of the corresponding genomic regions. As a conclusion, colorectal cancer is a heterogeneous disease, demonstrated by the genomic profiles of individual samples. However, our data shows that copy number changes do not occur exclusively in the MSS phenotypes.
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Introduction
The majority of colorectal cancers (CRC) are considered sporadic, having developed from an accumulation of mutations through the course of a lifespan. Genetic instability is a defining characteristic of most of cancer cells. Two forms of genetic instability have been identified in sporadic colorectal tumors: chromosomal instability (CIN), and microsatellite instability (MSI). Briefly, 480% of CRCs correspond to CIN tumors. They are caused by mutations in genes that are required to maintain chromosomal stability, leading to the accumulation of gains and losses of chromosomes (aneuploidy) as well as by structural chromosomal rearrangements (1) (2) (3) . On the other hand, MSI tumors show mutations in the mismatch repair genes leading to mutations in microsatellite DNA sequences and in genes close to them (4, 5) . These tumors usually show a stable, diploid karyotype. Nevertheless, recent studies have demonstrated that MSI tumors can also present genetic imbalances (6) , and both forms of genetic instability can coexist in some colorectal primary tumors (7) and cell lines (8, 9) .
The molecular cause of genomic instability is one of the most active research areas in cancer biology. MSI tumors are characterized by mutations in proofreading genes coding for mismatch repair enzymes, such as MLH1, MSH2, PMS1 and PMS2 (10, 11) , and by silencing the hMLH1 promoter by methylation. Somatic mutations in APC (5q), DCC, SMAD2 and SMAD4 (18q), TP53 (17p), KRAS (12p) and b-catenin (3p) genes are involved in CRC tumorigenesis (12, 13) . Other genes related to CIN tumors have also been reported. Thus, genes affecting the double-strand breakage repair mechanisms, e.g. MRE11, ATM, ATR, BRCA1 and BRCA2, and genes involved in ploidy maintenance and the chromosomal segregation, e.g. BUB1B (14) and SMAD4 have been demonstrated to be involved in the genomic stability of cancer cells.
Classical cytogenetics from primary colorectal tumors reported that the most frequent numerical changes were, in order of decreasing frequency, þ7, À18, À14, þ13 and À22. The gains of chromosome arms 8q, 17q, 20q, and the losses of 8p and 17p are also unbalanced chromosomal alterations previously identified (15, 16) . To overcome G-banding limitations, conventional comparative genomic hybridization (CGH) has been used to detect aneuploidies and chromosomal alterations in colorectal tumors (17) (18) (19) (20) . In these studies, CRCs have often shown extra copies of chromosomes 1, 13, and 20 and of chromosome arms 7p and 8q, whereas chromosome 4 and chromosome arms 8p and 10q were frequently underrepresented. Cytogenetic/CGH data are documented in the Mitelman Database of Chromosome Aberrations in Cancer (http://cgap. nci.nih.gov/Chromosomes/Mitelman), and at www.helsinki.fi/ cmg (21) .
Recently, microarray technologies have provided new ways to explore genomic imbalances and different gene expression (22, 23) . Array-based CGH represents a magnificent tool to study gene dosage imbalances in solid tumors (24) . Recent studies using bacterial artificial chromosome (BAC)-arrays covering the human genome at about 1 Mb resolution have been reported in CRC (25) (26) (27) . Consistent frequencies of copy number changes were identified, including gains of chromosomes/chromosome arms 20q, 8q and 13. Losses of chromosomes/chromosome arms 18q, 17p, 18p, 8p and 14q were frequently found, whereas minor losses were detected at 1p, 4q, 5q and 15q. A recent study established a genetic signature which could be used in clustering CRCs according to Dukes' stages (28) . Moreover, six differentially expressed genes were found in CIN and MSI phenotypes cell line analysis (29) .
The purpose of the present study was to investigate genomic imbalance differences between microsatellite stability (MSS) and MSI CRCs, using metaphase CGH (mCGH), array-CGH (aCGH) and expression arrays to assess gene expression profiles. Moreover, two cell lines, HCT116 (MSI archetype) and SW480 (CIN archetype), whose molecular karyotype have been described in our laboratory (30, 31) were also analyzed by both CGH methods. Our aim was to generate a comprehensive picture of the genomic alterations that occur differentially in both forms of colorectal tumors, and to identify chromosomal regions that may contain candidate genes important for the development of cancer cells.
Materials and methods

Tumor samples and cell lines
A total of 31 fresh-frozen colorectal tumors (16 MSS and 15 MSI) from Dukes' stages A-D were used for this study. Twenty-eight of these samples were used in the mCGH analysis, of which nine were further analyzed by aCGH and four by expression arrays. One sample was used for aCGH only, and two for expression analysis only. Samples were kindly provided by Dr Miguel A. Peinado from Institut de Recerca Oncològica, Hospital Duran i Reynals and Dr S. Schwartz Jr from Hospital Universitari Vall d'Hebron, Barcelona. Clinical characteristics are listed in Table I . MSI status was analyzed as previously described (32). None of the patients with MSI tumors showed hereditary non-polyposis colorectal (HNPCC)-related family history according to the Amsterdam Criteria (33) . Additionally, two CRC cell lines were used in the present study: HCT116 and SW480 (ATCC; Manassas, VA). Both were cultured using DMEM medium supplemented with fetal bovine serum 10% and glutamine 1%. Genomic DNA was extracted by the phenol-chloroform method. Before extraction, evaluation by the pathologist determined that the proportion of tumor cells was higher than 60%. Reference DNA for CGH hybridizations was extracted from peripheral blood lymphocytes of healthy individuals.
Total RNA from six primary tumors (three MSS and three MSI) and from adjacent tissue with a normal histology, was isolated using the RNeasy Mini Kit according to the manufacturer's protocol (Qiagen; Hilden, Germany). Two samples included in the gene expression profiling were not analyzed by CGH. Prior to microarray hybridization, the integrity of total RNA was confirmed using a 2100 Bioanalyzer (Agilent Technologies; Palo Alto, CA).
Metaphase CGH
Metaphase CGH (34) was performed as previously described (35) . Slides were analyzed using the Isis Imaging System, Metasystems software (Altlussheim, Germany). Ratio values 41.25 and 50.75 were considered as chromosomal gains and losses, respectively. Values were log 2 transformed for plotting purposes. Sex chromosomes were not taken into account in the analysis.
CGH on cDNA microarrays (aCGH)
Array-based CGH experiments were conducted as previously described on commercial cDNA microarrays (Human 1.0; Agilent Technologies) containing clones of approximately 13 000 genes (36) (37) (38) . Of these clones 982 had replicates on the array. Briefly, 20 mg of reference and sample DNA were digested with Alu1 and Rsa1 restriction enzymes (Life Technologies; Rockville, MD). Digested samples were purified using the basic phenolchloroform method. Labeling was performed as previously described (23) . Briefly, six mg of digested tumor and reference DNA were labeled with Cy3-dUTP and Cy5-dUTP (Amersham Biosciences; Piscataway, NJ), respectively, by RadPrime DNA labeling system (Gibco BRL; Gaithersburg, MD). Hybridization and post-hybridization washes were carried out as previously described (37) . Slides were scanned using an Agilent laser confocal scanner (G2565AA). Microarray images were analyzed with the Feature Extraction software (version 6.1.1, Agilent Technologies) using the locally weighted linear-regression curve fit option. Only those probes with a known position in the genome (10 080 probes) according to genomic alignment information available at the University of California at Santa Cruz (UCSC) Genome Browser Database (http://genome.ucsc.edu/, April 2003 freeze) were selected. Filters, if any, were applied to the aCGH datasets. However, given the high density of spots per chromosome on the aCGH, visual interpretation of known genomic lesions in plots of raw data was obscured by even a small percentage of the outlier probes. Therefore, we computed LOWESS smoothing lines in the data with an 'f' span equal to 0.2 (39) . These parameters were determined by comparisons between mCGH and aCGH results obtained in the laboratory. To identify statistically significant transitions in the copy number, we defined the variation of the copy number as log 2 AE2 SD of the middle 50% quantile of data. Also, we used a developed statistical segmentation algorithm termed circular binary segmentation (CBS), which parses the probe ratio data into segments of similar mean after taking the variance into account. The algorithm works by analyzing one chromosome at a time and, within that chromosome, recursively identifying the best possible segmentation. Each proposed split is accepted or rejected based on the probability that the difference in mean could have arisen by chance. This probability is determined using a randomization method (40) .
Gene expression microarrays
For gene expression profiling, GeneChip Human Genome U133 plus 2 oligonucleotide microarray (Affymetrix; Santa Clara, CA) was used, which contained 47 000 probe sets. Target cDNA preparations from total RNA, hybridization on the microarray, washing and staining with the antibody amplification procedure, and scanning were all carried out according to the manufacturer's instructions (Affymetrix). Arrays were scanned using an Affymetrix GeneChip Scanner 3000 and analyzed with Affymetrix Microarray Suite 5.0 (MAS 5.0). Detection values (present, marginal or absent) were determined by default parameters, and signal values were scaled by global methods to a target value of 100. Minimal quality control parameters for inclusion in the study included present calls 430% and a GAPDH 3 0 /5 0 ratio 53. To process and normalize U133plus2 Affymetrix chips, and the RMA (Robust Multichip Averaging) algorithm were used (41) . Differentially expressed genes between MSS and MSI were detected computing the B statistic (42) . All these computations were performed using the Bioconductor package (43) .
Results mCGH Metaphase CGH analysis was performed for 28 colorectal tumors (15 MSS and 13 MSI) and two cell lines (HCT116 and SW480). The chromosomal imbalances are represented in Figure 1 . The mean of chromosomal imbalances for MSS tumors (13 AE 8.46) was higher than the mean for MSI tumors (9 AE 4.58). Nevertheless, these differences were not statistically significant (0.05 5P 50.1, Mann-Whitney U test). Only one primary tumor belonging to the MSI group did not show any chromosomal imbalance. Interestingly, three tumors included in the MSS group displayed 525% ( 4) chromosomal imbalances according to the mean, and they were not scored in the mean. The imbalances of separate chromosomal arms are represented in Figure 2 . Chromosome losses in MSI tumors were very infrequent. Only chromosomes 5q, 2q and 4q (all 29%) (all IC 95 ¼ 53.3-6.6) were lost. Minimal common altered regions were defined as overlapped regions for gains or losses detected in at least four primary tumors. In general, we found 10 minimal regions in MSI and 17 regions in MSS tumors. Gains at 1p35pter, 8q24, 9q34, 11q13, 12q24.3, 16q24.3, 17q21 and 17q25, and losses at 5q21 were common findings in both types of tumors. MSS tumors showed statistically significant, specific losses at 1p22 and 4q26 (all P 50.05, x 2 test), whereas 6q22q24, 8p23, 14q11q24 and 15q21 showed a tendency to be lost (all 0.05 5 P 5 0.1, x 2 test). Minimal chromosome gains in MSS tumors appeared at 13q11q14, 13q34 (both 0.05 5 P 5 0.1, x 2 test). Minimal chromosome changes specifically found in MSI tumors were the gain at 22q13.3. This difference was statistically significant (P 5 0.05, x 2 test).
Array-CGH Array-CGH was performed on 10 samples (4 MSS and 6 MSI), nine of which were analyzed by mCGH. The reliability of the analysis was evaluated by comparing the results obtained in the two cell lines, HCT116 and SW480. A total of 83% of losses and 71% of gains detected by mCGH were also detected by aCGH. In addition, multiple alterations not detected using mCGH were identified by the microarray-based method (Table II ) (Figure 3A-D) . In the SW480 cell line, genes 
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residing within chromosomal regions apparently gained by mCGH, and showing a copy number ratio greater than 1.5-fold were located at 5q35.3 (STK10), 7q33-q35 (RhoGEF5), 8q24.2 (C-MYC), 11q13.3 (CCND1 and VEGFB), 12p12.1 (SIAT8A) and 12q14 (RAP1B). HCT116 showed 8q24.2 (C-MYC), 11q13.3 (CCND1) and 16q24.3 (CDK10) as gains. Although the HTC-116 cell line is derived from a familial cancer, it is widely used in modeling sporadic MSI cancers (MSI archetype).
The results of the tumor sample mCGH profiles corresponded well with the array results (Table III) . In general, the coincidence of array and mCGH was $60% (Figure 3E-F) . Two out of four MSS samples did not display any genetic alteration detected by aCGH. In only one MSS sample CMYC amplification was detected. The loss of chromosome 17p was found in one MSS sample. Target genes to be lost were XIAP associated factor-1, PRPSAP2, TP53, CD68 and ALOXE3. In MSI samples, aCGH an amplification peak at 1q31.3 was found, involving PLA2GA4, TAF1A, ACTN2 and CR2 genes. A loss at 2p16p21 was detected in sample # 274T with the corresponding genes CYP1B1, SLC8A1 and GPR75. Deletions at 15q21q22 involved TRPM7, RAB11A and MAP2K5. A gained region at 17q25 involved PC2, MAFG, USP14, COLEC12 and VYES1. Metaphase CGH was not performed on sample #123T because of lack of material, but aCGH showed a gain of chromosome 20, involving PDYN, GAL3ST1, PROCR, SRC and PPP1R16B. Four cases, including one MSS and three MSI, showed the loss of 5q13.3q21, a chromosomal region found also by mCGH in 35% of samples. CCNH, FER and RASA1 genes were the most frequently involved in this region according to our aCGH results. 
Differentially expressed genes
The gene expression experiments were performed on six samples (3 MSS and 3 MSI) of which four were used in mCGH analysis. More than 100 genes appeared to be differentially expressed when comparing three MSS to three MSI tumors. Clustering analysis allowed us to describe a total of 28 genes that were specifically over-or under-expressed in MSS or MSI samples (Figure 4) . The gene ontology database (AmiGO, http://www.godatabase.org/cgi-bin/amigo/go.cgi) was used to postulate tentative gene functions. The genomic locations of the over-and under-expressed genes were sought to obtain possible correlation with CGH data, and thus find the possible target genes of the amplified and lost regions detected by CGH.
Discussion
The genomic instability of CRC is widely accepted. It is unlikely that the DNA copy number alterations observed in colorectal tumors occur non-randomly, but rather they involve particular regions of the genome. In the present study, genomewide chromosomal imbalances and gene expression profiles in MSS tumors were compared with those in MSI tumors by using mCGH, aCGH and expression microarrays. The present study shows chromosomal differences, putative imbalanced genes and possible target gene identification by expression profiling in two phenotypes of colorectal tumors and cell lines categorized according to their MSS. The aCGH results were comparable to mCGH, as exemplified with the two cell lines. However, aCGH showed new chromosomal imbalances, especially losses. In addition, most of the regions undetected by aCGH (1p36, 9q34, 11q13, 12q24, 16p, 19 and 22 ) belonged to chromosomal areas that have been reported as problematic in mCGH, due to the GC-content (44) . In general, it is suggested that MSI colorectal tumors show a stable karyotype (1) . Recent aCGH studies performed on MSI tumors showed gains at 20q, 8p, and 8q24.3, and losses at 18q21.1q21.2 (27) . Our aCGH data suggested particular copy number alterations affecting other chromosomes in MSI tumors (Table III) . Most of the MSS colorectal tumors are suggested to show CIN mainly characterized by the prevalence of aneuploidy and structural alterations (2, 3, 45) . Our data showed three MSS tumors with a very low number of chromosomal imbalances, similar to the MSI-CIN À group of colorectal tumors studied by Jones et al. (26) . Nevertheless, we did not detect the loss of chromosome 20p, the only change that the authors found to be significantly overrepresented in MSI-CIN À cancers compared with MSI-CIN þ tumors. Amplifications are indicated in bold face.
Genomic alterations in MSS and MSI colorectal tumors
In agreement with previous data of mCGH (17, 46, 47) , we detected gains of 20q and 8q and loss of 18q as the most frequent alterations in MSS cancers. Gains of 17q, 20p, 7q and 13q, and losses of 4, 15q, 5q, 8p, and 14q, in order of decreasing frequency, were also detected. Minimal chromosomal imbalances found to be significantly specific to MSS tumors were losses at 1p22 and 4q26. The former has been postulated as a prominent deletion in CRC (48) . The deletion of chromosome 4 has already been shown to be involved in the adenoma to invasive carcinoma progression (48) and the involvement of 4q26 has also been proven (49) . The regions 6q22q24, 8p23, 14q11q24 and 15q21 showed a tendency to be lost in MSS tumors, while 13q11q14 and 13q34 tended to be gained. The presence of a putative tumor suppressor gene in the distal part of chromosome 8p has been proposed (50) , and the region 15q21, although infrequently affected in CRC, is suggested to harbor a tumor suppressor gene (51) . Interestingly, several down-regulated genes at 15q21 
have been reported, including THBS1 and ITA3 (28) , and this region has been linked to adenoma-carcinoma progression (52) . The results of the present study show that gains of 17q, 22q, 8q and 20q and the losses of 5q, 2q, and 4q occur frequently in MSI CRCs. Previous findings reported gains of 4q and 8q, and losses of 9q, 1p and 11q (53) , or genomic stability (54) as the most common features in MSI tumors. However, in the present study only one of the 15 MSI tumors was genetically stable. A preferential gain of 22q13 was also observed. A previous mCGH report found MSI CRCs chromosomally stable, whereas the non-MSI tumors showed 7, 13 and 20q gained and 17, 18 and 9p lost (52, 54) .
Several minimal regions occurring both in MSS and MSI tumors were found, e.g. gains at 8q24, 16q24.3, 17q21, 17q25 and 20q13.2q13.3, and loss of 5q21. The latter region is known to contain the tumor suppressor gene APC, which mutations and allelic imbalances are considered the earliest and most prevalent genetic changes in CRC, coinciding with the CIN pathway (1, 55) . According to several authors (56, 57) , loss of heterozygosity at 5q is also present in patients with HNPCC. Considering that the Amsterdam Criteria are liable to miss many cases of HNPCC, the MSI samples may include some HNPCC patients. In the present study 29% (8/28) of the samples showed loss of 5q21 on mCGH, and 40% (4/10) by aCGH ( Figure 1 , Table III ). However, as it is well known that allelic imbalances affect more than one single gene, several candidate genes believed to be involved in the loss of 5q14q21 were identified by aCGH, e.g. CCNH, FER and RASA1. FER is a member of the SRC tyrosine kinase gene family, and has been associated with the loss of 5q21 in e.g. myeloid leukemia (58) and lung cancer (59) . Moreover, it has been suggested that Fer may be a potential target for modulators of malignant cell growth (60) . We detected gains of 8q24 in both MSS and MSI tumors; however, the resolution of mCGH did not allow delineation of the target of amplification, which has been reported to vary according to MSI status (27) . Recent findings have also demonstrated alterations in chromosome 8 in MSS and MSI tumors (25) . The gain in chromosome 20q is thought to be an early event occurring in the transition from adenomacarcinoma progression (17) , and it has been associated with poor survival in several studies (20, 47) . The gain of 20q13.2q13.3 has already been associated with colorectal carcinogenesis and metastatic progression in CRC (61) (62) (63) . A gain of 16q24.3 was also frequently gained in our samples, including the HCT116 cell line ( Figure 3B ). Array-CGH data showed several putative target genes, including CDK10 and DPEP1, which were also found to be over-expressed in MSS samples with a 16q24.3 gain. DPEP1 has already been suggested as a tumor-specific molecular marker for disseminated colon tumor cells (64) . Gene expression analysis revealed differences between MSS and MSI tumors. MAGE and CTNNB1 were detected over-expressed in MSI tumors. CTNNB1 (encoding for the activating somatic b-catenin) mutations are common in HNPCC tumors (65) . In recent studies, MAGE has been described as a biomarker to detect micrometastasis (66) and it has been significantly associated with the vessel emboli in CRC (67) . However, none of the samples analyzed here, and which showed over-expression of MAGE, presented metastasis. Further studies will be required to demonstrate the role of those genes that appear to be differentially expressed between MSS and MSI tumors according to our results.
As a conclusion, CRC is a heterogeneous disease with many molecular phenotypes. In the present study we studied both microsatellite stable and unstable phenotypes by their copy number changes. Both the phenotypes were shown to have both stable and unstable chromosomal structures, suggesting involvement of multiple mechanisms in CRC carcinogenesis. Over-expression of CDK10 and DPEP1 was found in samples with amplification at the corresponding genomic region (16q24.3), and therefore they may be considered as putative target genes. However, more samples are needed for validation studies.
